Abstract: Nonadherence to topical treatment of psoriasis is a common cause of treatment failure. This focus group study was conducted to obtain the patients' own experiences and explanations regarding medical adherence. The participants consisted of eight primary adherent patients with moderate psoriasis treated with corticosteroid or corticosteroid-calcipotriol combinations, purposefully sampled by age and sex at a dermatology outpatient clinic. Secondary medical adherence was supported by accessibility of the prescribing physician, the prescriber taking time to listen, having a more manageable disease, using a nonstaining product, and establishing routines around treatment at home. Secondary medical adherence was affected negatively by changes in daily routines, if the treatment influenced the patient's sexual life, having too little time in the consultation room, lack of confidence in the prescriber, diverging information from health care personnel, experiencing side effects, having fear of side effects, impractical formulations of topical products, and impatience regarding time before an effect of the treatment was observed. From this study, the recommendations for the prescribing doctor to improve medical adherence are, the doctor needs to take time to listen to the patient, prescribe a topical product that is easy to apply and less greasy, inform the patients about benefits from treatments, and explain the rationale behind the treatment plan.
Introduction
Psoriasis is a chronic disease with a prevalence rate of 2%-4% in the Western population. 1 Topical corticosteroids and corticosteroid-calcipotriol combinations constitute first line of treatment. In chronic diseases, one of the main causes of treatment failure is medical nonadherence. 2 In patients with psoriasis, the rate of medical nonadherence to topically prescribed corticosteroids or corticosteroid combinations is reported to range from 8% to 88%, 3, 4 addressed in studies using heterogeneous study designs. The multifactorial determinants of medical nonadherence to topical corticosteroids and corticosteroid/calcipotriol combinations have mainly been investigated in survey studies, 5, 6 while only briefly described in qualitative studies. 7, 8 This led us to conduct this study, to get the patients' own experiences and explanations on medical adherence.
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Svendsen et al Table 1 Participant demographics and medical history in focus group held for men In addition, all patients reported being primary adherent 6 months prior to the study.
Abbreviation: DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; NB-UVB, narrowband ultraviolet B phototherapy. Tables 1 and 2 ). One focus group was held for men and another for women. The study was conducted in accordance with the World Medical Association's Declaration of Helsinki. Eight primary adherent patients suffering from psoriasis took part in the study, five men and three women. The age range was 20-66 years, with a median age of 43.5 years. The focus groups were led by MTS and HJ in a conference room at the hospital. To demonstrate primary adherence, the patients were asked to bring all the packages of corticosteroids and corticosteroid-calcipotriol combinations they had at home. Initially, while placing the packages on the table in front of them, the patients were briefly asked to introduce themselves and tell about their disease and use of topical antipsoriatics. After this, we continued to discuss reasons for medical nonadherence. The discussions were grouped in five consecutive sections according to the determinants of nonadherence defined by the World Health Organization (WHO) 9 listed in Table 3 . We used audio recording and continued until all points were discussed. Each focus group lasted ~100 minutes.
The audio records were transcribed and thereafter manually coded by MTS. In the evaluation, we used deductive qualitative content analyses based on WHO's five categories for determinants affecting adherence. Codes were grouped into larger categories. Uniformities and variations were revealed by MTS and HJ in a comparative process.
Ethics
Ethical approval was not required for this study according to Danish law. A signed consent was obtained from all participants before the focus groups were held.
Results
All reported determinants influencing medical adherence are given in Tables 4 and 5 . Medical adherence was supported by living with a partner, accessibility of the prescribing physician, the prescriber taking time to listen, having a more manageable disease, using a nonstaining product, and establishing routines around treatment at home (Table 4) . In contrast, medical adherence was negatively affected by changes in daily routines, if the treatment influenced the patient's sexual life, having too little time in the consultation room, lack of confidence in the prescriber, diverging information from health care personnel, experiencing side effects, having fear of side effects, impractical formulations of topical products, and impatience regarding time before an effect of the treatment was observed ( Table 5 ). The price of medication was considered high, but the participants prioritized to buy the medication or had the medication paid for by health insurance or family members. Although some of the patients expressed a wish for an effective treatment, they also reported discontinuing treatment when it worked. Six out of eight patients used complementary approaches as a supplement to prescribed treatments; most commonly sun bathing and vitamin supplements (Table 6) .
Discussion
This study adds information on important aspects of living with psoriasis, a disease requiring topical treatment that is both time consuming and impractical for the patient. Using a qualitative research design helped us to provide insight into the nonmeasurable aspects of the patient's perceptions on medical drugs and daily life. The results from our study may not be representative of all patients with psoriasis. This is stressed by the patients described in this study all being primary adherent and having regular checkups at the hospital clinic. To identify differences in determinants of nonadherence between primary versus secondary nonadherent patients, we recommend future studies to be conducted among topically treated primary nonadherent psoriasis patients. Potentially, participants could also be sampled from other settings, ie, general practice or private dermatologists. The study findings align with those reported in the international literature. In relation to social/economic factors, adherence was limited when patients experienced the disease influencing on their intimate life, 10 but improved by receiving support from their partner. 3 Considering treatment factors, adherence was limited when patients experienced the treatment as greasy, 5 but improved when treatment was easy to apply. 5, 11 In relation to the health care system, adherence was limited when patients experienced uncertainty regarding the rationale Reducing stress "My wife encourages me to apply the cream." Jonah "My wife checks my skin for flare-ups, because I don't." Jake "I apply the gel more carefully if I need to go somewhere." Kimberly "It's more comfortable if I look good when we're going out." Jake "When I'm going on a date, I'm concerned about my psoriasis." Romeo "Habits and rituals help me […] If I bring the gel with me to the swimming pool I will remember to use it." Kimberly "I worked on an oil rig; it was a daily routine. As long as I was there, I used the cream every day." Charlotte "I get a lot of prescription subsidies so it's not expensive." Mike "My parents pay for the cream." Arthur "I get so much prescribed medication that I actually get the expenses covered by the health insurance. 
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Svendsen et al behind the treatment plan, 6, 7, 12 but improved from confidence in the prescriber. 6 In relation to the disease, adherence was limited by having areas difficult to reach, 6 but improved when suffering from widespread disease. 6 In relation to the patients themselves, adherence was limited by patients terminating treatment when initial positive treatment results were reached, 5 but improved by establishing routines in their everyday life. 5, 12 In addition to previous research, this study showed that the patients received help from their partner in checking the skin for flare-ups and assisting in greasing.
Treatments need to be continued after they have shown an initial beneficial effect. Further research is needed to elucidate the effect of, eg, early follow-up visits 13 or use of technical support on adherence. Technical support could include sending mobile phone reminders 14 or use of patient-supporting apps delivered by smartphones. For the prescriber to help improve adherence, the recommendations from this study are the doctor needs to take time to listen to the patient, prescribe a topical product that is easy to apply and less greasy, inform the patients about benefits from treatments, and explain the rationale behind the treatment plan. 
